NeuroRx, Inc. is a clinical stage pharmaceutical company that is developing NRX-101, the first oral therapeutic for the treatment of Acute Suicidal Behavior/Ideation (ASIB) in Bipolar Disorder. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain’s N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. NeuroRx’s investigational treatment approach begins with a single dose of ketamine, an FDA approved anesthetic, followed by approximately six weeks of daily oral NRX-101. NRX-101 is being developed as a rapid-onset and sustained treatment for acute suicidal crisis associated with bipolar depression. NRX-101 combines D-cycloserine, an N-methyl-D-aspartate (NMDA) receptor modulator; and lurasidone, a 5-HT2a receptor antagonist. Peer-reviewed and published results from two Phase II clinical studies demonstrate a significant decline in symptoms of depression and suicidality following administration of D-cycloserine. Findings from one of these studies found that bipolar patients who were already receiving a 5-HT2a antagonist demonstrated more than a 50% reduction in symptoms of depression and a 75% reduction in suicidal ideation when ketamine and D-cycloserine were added to their treatment regimen. Side effects for patients in a P2a combination study of D-cycloserine and 5HT2a included mild sedation, headaches and hypomania
View Top Employees from NeuroRx PharmaWebsite | http://www.nrxpharma.com |
Ticker | NRXP |
Employees | 19 (19 on RocketReach) |
Founded | 2015 |
Address | 1201 Orange St Ste 600, Wilmington, Delaware 19801, US |
Phone | (484) 254-6134 |
Industry | Pharmaceuticals, Biotechnology, Pharmaceutical Development, Healthcare, Science and Engineering, CNS, Pharmaceutical, Medical Device Development, Health Care, Acute Suicidality |
Web Rank | 7 Million |
Keywords | "Esketamine" And "Breakthrough Therapy Designation", Role Of Calcium, Glutamate And Nmda In Major Depression And Therapeutic Application., Nmda-Receptor, Neurorx |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 54 Companies, NAICS Code 541711 Companies, NAICS Code 541 Companies, NAICS Code 5417 Companies |
Looking for a particular NeuroRx Pharma employee's phone or email?
Steve Willard is the CEO of NeuroRx Pharma.
19 people are employed at NeuroRx Pharma.
NeuroRx Pharma is based in Wilmington, Delaware.
The NAICS codes for NeuroRx Pharma are [54171, 54, 541711, 541, 5417].
The SIC codes for NeuroRx Pharma are [283, 28].